Clinical Scorecard: Combination of post-transplant cyclophosphamide and everolimus for preventing graft-versus-host disease in resistant T- and B-cell lymphomas
Post-transplant cyclophosphamide (PTCy) preserves regulatory T-cells and spares hematopoietic stem cells; everolimus provides immunosuppression with anti-neoplastic and anti-viral effects
Target Population
Patients with relapsed and refractory aggressive B-cell and T-cell non-Hodgkin’s lymphoma or Hodgkin’s disease
Care Setting
Allogeneic hematopoietic stem cell transplantation units with reduced-intensity conditioning
Key Highlights
PTCy combined with everolimus showed low rates of severe acute and chronic GvHD in a cohort of 33 lymphoma patients.
Overall survival was 64% at 1 and 2 years; progression-free survival was 58% and 55% at 1 and 2 years respectively.
Non-relapse mortality remained a challenge at 24.2% at 1 and 2 years, mainly due to septic complications.
Guideline-Based Recommendations
Diagnosis
Assess aggressive lymphoma subtype and refractory status prior to allogeneic HSCT.
Evaluate prior therapies including CAR-T cell treatment.
Management
Use reduced-intensity conditioning with fludarabine and busulfan.
Administer PTCy intravenously on days 3 and 4 post-transplant at 50 mg/kg/day.
Start everolimus from day +5 to day +100 post-transplant targeting blood levels of 5–10 ng/ml.
Monitoring & Follow-up
Monitor neutrophil and platelet recovery post-transplant.
Assess GvHD according to 2014 NIH criteria, focusing on grade III-IV acute and systemic immunosuppression-requiring chronic GvHD.
Regularly evaluate for relapse and non-relapse mortality causes.
Risks
Risk of acute GvHD remains (63.6% overall; severe grade III-IV in ~12%).
Chronic GvHD occurred in 21.2%, with 9.1% requiring ongoing systemic immunosuppression.
Non-relapse mortality at 24.2% mainly due to infections and septic complications.
Patient & Prescribing Data
33 patients with relapsed/refractory aggressive lymphomas, median four prior therapies, including CAR-T cell therapy in some.
Combination of PTCy and everolimus is feasible and associated with favorable graft-versus-host disease control and survival outcomes, with manageable hematological toxicity and no new non-hematological safety concerns.
Clinical Best Practices
Consider PTCy plus everolimus as GvHD prophylaxis in matched-donor aHSCT for resistant aggressive lymphomas.
Use reduced-intensity conditioning to balance efficacy and toxicity.
Close monitoring for infections is critical due to significant non-relapse mortality from septic complications.
Evaluate prior CAR-T therapy timing and impact on transplant outcomes.
Apply NIH 2014 criteria for standardized GvHD assessment.
by Tim Richardson, Hishan Tharmaseelan, Lukas Frenzel, Philipp Gödel, Moritz Fürstenau, Pascal Nieper, Till Braun, Daniel Schütte, Michael Hallek, Christof Scheid, Udo Holtick
